The agreement, whose specific terms were not disclosed, is subject to Laurantis gaining approval for Phase I trial that is scheduled to begin in 2013.
Lymfactin leverages an adenoviral vector to transport vascular endothelial growth factor during lymph node transplantation in a course to avoid lymphedema.
The Phase I trial of Lymfactin is expected to recruit patients in the US and Finland.
At present no therapeutic treatment exists to treat breast cancer-associated lymphedema, the common form of secondary lymphedema, according to the companies.